
A study evaluated the efficacy and safety of estetrol (E4) 15 mg combined with drospirenone (DRSP) 3 mg for treating endometriosis-associated pain in Japanese women. Results showed significant reductions in pelvic pain and improvements in gynecological findings with E4/DRSP compared to placebo. The treatment also reduced endometrioma size and enhanced quality of life, with no significant safety concerns, suggesting E4/DRSP as a promising option for endometriosis treatment.
Like
Save
Share